Get the Stockscreener App
12.03
3.22%
-0.40
After Hours:
12.02
-0.010
-0.08%
Fibrogen Inc stock is traded at $12.03, with a volume of 13,107.
It is down -3.22% in the last 24 hours and up +30.05% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$12.43
Open:
$12.43
24h Volume:
13,107
Relative Volume:
0.23
Market Cap:
$48.65M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-4.1058
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-0.58%
1M Performance:
+30.05%
6M Performance:
+4.54%
1Y Performance:
+13.68%
1-Day Range:
$11.84
$12.44
1-Week Range:
$10.88
$12.53
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
12.03 | 46.55M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
$1.25 million penalty for FibroGen over ‘false and misleading statements’ case - The Pharma Letter
FibroGen at H.C. Wainwright: Strategic Moves and Future Prospects By Investing.com - Investing.com Nigeria
FibroGen at H.C. Wainwright: Strategic Moves and Future Prospects - Investing.com
Is FibroGen Inc. stock a buy or sell2025 Biggest Moves & Growth-Oriented Investment Plans - Lancaster City Council
FibroGen To Pay SEC $1.25M Over Drug Mistatements - Law360
Can FibroGen Inc. reach all time highs this yearJuly 2025 Review & Smart Money Movement Tracker - beatles.ru
FibroGen Sells Subsidiary to AstraZeneca for $220 Million - The Globe and Mail
Smart tools for monitoring FibroGen Inc.’s price action2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - Newser
Is FibroGen Inc. exposed to currency risksChart Signals & Consistent Return Investment Signals - خودرو بانک
Is FibroGen Inc. affected by consumer sentimentMarket Growth Report & Short-Term High Return Strategies - خودرو بانک
Using Python tools to backtest FibroGen Inc. strategiesJuly 2025 Rallies & Real-Time Market Trend Scan - Newser
FibroGen completes $220 million sale of Hong Kong subsidiary to AstraZeneca - Investing.com Canada
FibroGen completes $220 million sale of Hong Kong subsidiary to AstraZeneca By Investing.com - Investing.com South Africa
Using data filters to optimize entry into FibroGen Inc.July 2025 Sector Moves & Daily Volume Surge Signals - Newser
What is FibroGen Inc. s 5 year growth outlookJobs Report & Risk Managed Investment Signals - خودرو بانک
What’s the analyst consensus on FibroGen Inc.Weekly Loss Report & Weekly High Momentum Picks - خودرو بانک
FibroGen Inc. stock outlook for YEARWeekly Profit Analysis & AI Forecasted Stock Moves - Newser
How sentiment analysis helps forecast FibroGen Inc.Bond Market & Community Shared Stock Ideas - Newser
Regression analysis insights on FibroGen Inc. performance2025 Top Decliners & Step-by-Step Swing Trade Plans - Newser
How hedge fund analytics apply to FibroGen Inc. stockJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - Newser
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment - GlobeNewswire
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecasts Report 2025-2030 | Boehringer Ingelheim and FibroGen Lead by Driving Innovations in Pharmacological and Diagnostic Advancements - Yahoo Finance
How does FibroGen Inc. score in quality rankings2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک
Using fundamentals and technicals on FibroGen Inc.Portfolio Value Report & Low Risk High Win Rate Stock Picks - Newser
Is a relief rally coming for FibroGen Inc. holdersMarket Growth Report & Long-Term Capital Growth Ideas - Newser
How to build a dashboard for FibroGen Inc. stockMarket Movers & Low Drawdown Momentum Ideas - Newser
FibroGen Sells Subsidiary to AstraZeneca for $220M - MSN
Aug Momentum: What are analysts’ price targets for FibroGen Inc.Inflation Watch & Stepwise Trade Execution Plans - خودرو بانک
Will FibroGen Inc. see short term momentumQuarterly Portfolio Report & Precise Entry and Exit Recommendations - Newser
Will breakout in FibroGen Inc. lead to full recovery2025 Risk Factors & Intraday High Probability Alerts - Newser
Is FibroGen Inc. stock a value trapDip Buying & Low Risk Entry Point Tips - خودرو بانک
Is FibroGen Inc. stock entering bullish territoryEntry Point & AI Forecasted Entry/Exit Points - Newser
Is FibroGen Inc. stock poised for growthQuarterly Market Review & Trade Opportunity Analysis - Newser
What is FibroGen Inc. s revenue forecast2025 Breakouts & Breakdowns & Fast Entry Momentum Alerts - beatles.ru
Price momentum metrics for FibroGen Inc. explainedQuarterly Investment Review & Weekly Watchlist of Top Performers - Newser
Can machine learning forecast FibroGen Inc. recovery2025 Analyst Calls & Consistent Growth Equity Picks - Newser
FibroGen stock maintains Buy rating at H.C. Wainwright after China sale - Investing.com Nigeria
Volume spikes in FibroGen Inc. stock – what they mean2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Using R and stats models for FibroGen Inc. forecastingWeekly Risk Report & Advanced Swing Trade Entry Plans - Newser
Is FibroGen Inc. stock forming a triangle patternJuly 2025 Setups & Verified Trade Idea Suggestions - khodrobank.com
What technical models suggest about FibroGen Inc.’s comebackEntry Point & Smart Investment Allocation Insights - Newser
What are analysts’ price targets for FibroGen Inc.July 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):